Zura Bio Ltd (ZURA) Form 10-Q — Oct 27, 2026
Zura Bio reported a Q3 2026 net loss of $25.8 million ($0.20 per share), with losses widening 43% year over year as R&D spending jumped 63% to $19.5 million to fund its Phase 2 tibulizumab trials in hidradenitis suppurativa, systemic sclerosis, and a newly initiated polymyalgia rheumatica program. The company holds $187.7 million in cash following its February 2026 equity offering, which raised approximately $134.6 million in net proceeds, and management states existing cash is sufficient to fund operations through at least the end of 2028.
Key figures
- Revenue
- 0
- Total Assets
- 194629000
- Cash Position
- 187652000
- Shares Outstanding
- 96325411
- Cash runway
- sufficient to fund operations through at least end of 2028
- Rd expense q3
- 19491000
- Accumulated deficit
- 300899000
- Operating expense q3
- 28773000
- Atm remaining capacity
- 114000000
- Rd expense q3 yoy change
- 63%
- Operating expense q3 yoy change
- 47%
- Pre funded warrants outstanding
- 29295396
- Net proceeds february 2026 offering
- 134600000
- Gross proceeds raised since inception
- 421500000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.